Seven abstracts highlight long-term effects, consistent safety profile, and delayed disease progression with givinostat Results also show that treatment is associated with delayed decline in respiratory function CONCORD, Mass. , March 17, 2025 /PRNewswire/ -- ITF Therapeutics LLC, the U.S.
affiliate of Italfarmaco, today announced the presentation of seven abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held March 16-19, 2025 , in Dallas, Texas . The poster presentations include data from the Phase 3 EPIDYS study and the company's ongoing open-label extension study in patients with Duchenne muscular dystrophy (DMD) treated with givinostat. Analyses assess the long-term safety and efficacy of givinostat as identified through measures including data on disease progression and respiratory function.
Please see the Indication and Important Safety Information for DUVYZATTM (givinostat) below. "This year's MDA Clinical and Scientific Conference arrives at a meaningful moment for our team as we reflect on the one-year anniversary of the U.S.
FDA approval of DUVYZAT for the treatment of DMD in people 6 years of age and older," said Matt Trudeau , President, ITF Therapeutics. "We are honored to participate in this important meeting and look forward to sharing new insights from our ongoing research, including clinical data from our open-label extension study in DMD. These abstracts assess the long-term efficacy and safety of DUVYZAT, and we.